Meridian Bioscience, Inc.  

(Public, NASDAQ:VIVO)   Watch this stock  
Find more results for Meridian Bioscience, Inc
16.59
+0.10 (0.61%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.28 - 16.77
52 week 15.80 - 27.72
Open 16.45
Vol / Avg. 331,728.00/312,504.00
Mkt cap 689.61M
P/E 20.09
Div/yield 0.20/4.82
EPS 0.83
Shares 41.57M
Beta 1.31
Inst. own 94%
Jan 20, 2015
Q1 2015 Meridian Bioscience Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 20, 2014
Meridian Bioscience Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 6, 2014
Q4 2014 Meridian Bioscience Inc Earnings Release
Sep 26, 2014
Vivoline Medical AB Extraordinary Shareholders Meeting
Sep 9, 2014
Meridian Bioscience Inc at CL King & Associates Inc Best Ideas Conference
Sep 3, 2014
Meridian Bioscience Inc at Robert W. Baird & Co. Inc Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 17.52% 18.40%
Operating margin 25.63% 27.75%
EBITD margin - 27.75%
Return on average assets - -
Return on average equity - -
Employees 550 -
CDP Score - -

Address

3471 River Hills Drive
CINCINNATI, OH 45244
United States - Map
+1-513-2713700 (Phone)
+1-513-2713762 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics and Life Science.

Officers and directors

William J. Motto Executive Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John A. Kraeutler President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Melissa A. Lueke Chief Financial Officer, Executive Vice President, Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marco G. Calzavara President and Managing Director of Meridian Bioscience Europe
Age: 59
Bio & Compensation  - Reuters
Lawrence J. Baldini Executive Vice President - Operations and Information Systems
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard L. Eberly Executive Vice President; President of Meridian Life Science
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Vecheslav A. Elagin Ph.D. Executive Vice President - Research and Development
Age: 46
Bio & Compensation  - Reuters
Susan D. Rolih Executive Vice President - Regulatory Affairs and Quality Assurance
Age: 64
Bio & Compensation  - Reuters
Marviette D. Johnson Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters
Dwight E. Ellingwood Director
Age: 61
Bio & Compensation  - Reuters